NSE: LUPIN | BSE: 500257 | Sector: Healthcare / Pharmaceuticals | CMP: ₹2,278 | Market Cap: ₹1,04,158 Cr

Lupin: US Recovery, India Growth Power Re-rating

Lupin Limited (LUPIN) is the 3rd largest pharmaceutical company in India by domestic sales and a top-tier global generics player with a footprint across 100+ countries, 15 manufacturing sites, and a portfolio of 1,800+ products. Founded in 1968 by Dr. Desh Bandhu Gupta, the Mumbai-headquartered firm has transformed itself from a domestic API-focused entity into a vertically integrated, US-FDA-approved, specialty-leaning pharmaceutical powerhouse. With Q4FY26 revenue of ₹7,475 Cr, net profit of ₹1,469 Cr, and trailing-twelve-month EPS of ₹116.65, Lupin is currently in the middle of one of the sharpest operational turnarounds in Indian pharma history — a story driven by US generic price stabilization, India brand dominance, and complex generics/complex injectables scale-up.

This comprehensive equity research report dissects Lupin's business model, 9-quarter trajectory, 5-year financials, peer competitive positioning, DCF fair value, analyst consensus, shareholding pattern, and key risks before synthesising a clear investment thesis. The base case is constructive: at ₹2,278, LUPIN trades at 18.1x trailing P/E with 30.3% ROCE, 29.1% ROE, and 5-year profit CAGR of 37% — a profile that historically rewards patient capital. We initiate with a BUY rating, a 12-month target of ₹2,750 (implied 20.7% upside), and a bull-case fair value of ₹3,200 under a more aggressive US-margin scenario.

§1 — Business Overview: The Lupin Group

Lupin is structured as a vertically integrated pharmaceutical company operating across four primary revenue engines: (i) US generics, the largest absolute contributor and the primary swing factor for consolidated margin; (ii) India formulations, a chronic-dominant branded franchise that delivers the highest gross margins in the portfolio; (iii) EMEA + growth markets, a steady ex-US international business anchored by the Nisoldipine / Namuscla / Etanercept biosimilar franchises and branded specialty sales; and (iv) Active Pharmaceutical Ingredients (API), the strategic foundation that supplies captive consumption and serves external customers. Across these, Lupin markets 1,800+ products spanning cardiology, diabetes, respiratory, anti-infectives, central nervous system (CNS), gastroenterology, women's health, oncology, and biologics/biosimilars.

1.1 Group Profile & Legacy

1.2 Revenue Segments — Mix & Strategic Role

1.3 Manufacturing & R&D Footprint

1.4 Key Therapeutic Franchises

Lupin's commercial portfolio is anchored by six therapeutic super-franchises that together drive roughly ~85% of branded revenue:

1.5 Strategic Acquisitions & Partnerships

1.6 Business Model — Vertical Integration & Margin Drivers

Lupin's business model rests on three pillars of value creation: (1) API-to-formulations vertical integration, which secures supply and cushions gross margins against external price spikes; (2) complex generics / specialty differentiation, which raises per-script profitability and reduces exposure to commoditized small-molecule pricing pressure; and (3) brand equity in India, where chronic-therapy loyalty creates a long-duration annuity stream. The economics are improving — OPM expanded from 1% in FY22 to 32% in FY26 — because of (a) US price erosion slowing after the 2022–23 trough, (b) India mix shifting toward chronic therapies (now >60% of India sales), (c) complex-generic launches (Solenor, Mirabegron, Sugammadex biosimilars), and (d) operating leverage on a fixed R&D and SG&A base. With 30.3% ROCE and 29.1% ROE, the business is now firmly in high-quality-compounder territory.

§2 — Latest Quarter Deep Dive: Q4FY26 & FY26 Full-Year

The March 2026 quarter (Q4FY26) is a defining quarter for Lupin. It marks the company's first full year of consolidated revenue above ₹27,000 Cr, its highest-ever full-year operating margin (32%), and its best-ever annual net profit (₹5,355 Cr). Sequential momentum is strong, with Q3 → Q4 sales rising from ₹7,168 Cr to ₹7,475 Cr (+4.3% QoQ), and Q2 → Q3 → Q4 EPS climbing ₹26.69 → ₹32.36 → ₹25.73 → ₹31.94, reflecting steady mix improvement and complex-generic scale-up.

2.1 Quarterly Trend (Last 13 Quarters)

Note: The screener.in source reverses fiscal-year-end labelling; figures are reported as published. The latest reported quarter is Mar 2026 (Q4FY26 in Lupin's internal convention).

2.2 Sequential Walk — Q3FY26 → Q4FY26

2.3 Year-on-Year Walk — Q4FY25 → Q4FY26

2.4 Annual P&L (FY22 → FY26)

2.5 Margin Bridge — FY22 OPM 1% → FY26 OPM 32%

2.6 Revenue-Mix Commentary by Segment (FY26 estimates)

2.7 Cash-Flow Performance (FY26)

Lupin's FCF of ₹5,527 Cr in FY26 is a structural milestone — it means the company can self-fund capex, dividend, and incremental working capital from operations, and still hold net cash buffer that has grown to ~₹3,000–3,500 Cr (after netting borrowings of ₹6,616 Cr against investments + cash of ~₹9,500 Cr).

§3 — 5-Year Financial Performance & Quality Assessment

The 5-year window FY22–FY26 captures Lupin's complete operational cycle: from the FY22 US price-cliff + impairment shock that drove the company to a ₹1,528 Cr consolidated loss and OPM of 1%, to the FY26 record-breaking year with ₹5,355 Cr net profit and 32% OPM. This is one of the sharpest pharma turnarounds in Indian markets.

3.1 Multi-Year P&L Summary

3.2 Compounded Growth Rates (Screener reported)

3.3 Balance Sheet Evolution (FY22 → FY26)

3.4 Return Metrics Trajectory

3.5 Quality Scorecard

3.6 Working Capital & Capital Efficiency

Lupin's cash conversion cycle has compressed by ~15 days in 3 years — a hallmark of management discipline and channel de-risking, particularly in the US business where large customers (wholesalers, GPOs) used to demand extended credit terms.

§4 — Industry & Competition: Pharma Peer Comparison

Lupin operates in the Indian Pharmaceutical Industry (IPI), a ~$50 Bn market growing at 10–11% CAGR, and the Global Generics market, a ~$130 Bn addressable market growing at 5–6% CAGR. India is the largest generic supplier to the US with ~40–45% of US prescriptions filled by Indian generics, and Lupin is among the top-3 Indian players by US revenue (alongside Sun Pharma, Aurobindo, Dr. Reddy's, Cipla).

4.1 Indian Pharma — Top 10 by Market Cap

4.2 Peer Comparison — Key Metrics

4.3 US Market Position — Indian Generics (Top 10 by US Sales FY25)

4.4 Competitive Strengths vs Weaknesses — Lupin

4.5 Industry Tailwinds & Headwinds

§5 — DCF Valuation

Our DCF model values Lupin using a 10-year explicit forecast (FY27E–FY36E) plus a terminal value computed via Gordon Growth Model. We use WACC of 10.5% and terminal growth of 5.0% to reflect Lupin's lower-risk profile post-turnaround and its industry-leading ROCE.

5.1 WACC Build-Up

5.2 Free Cash Flow Projection (₹Cr)

5.3 DCF Sensitivity (₹ per share)

5.4 DCF Scenario Summary

5.5 Cross-Check: Relative Valuation

5.6 Valuation Conclusion

We adopt a target of ₹2,750 based on a 60:40 blend of DCF (₹2,618) and forward-PE (₹2,700 at 20x FY27E EPS of ₹135). This implies 20.7% upside from ₹2,278, with the bull case fair value at ₹3,200 under a more aggressive US-margin / complex-generic scenario. Valuation risk-reward is favorable because the downside to ₹2,050 (stress case) is only 10% below spot, while the upside to ₹3,200 (bull case) is 40% above spot — a 1:4 reward-to-risk.

§6 — Analyst Consensus & Brokerage Views

Lupin is covered by ~30+ sell-side analysts, with major brokerages including Motilal Oswal, ICICI Securities, HDFC Securities, Kotak Institutional, Jefferies, Morgan Stanley, BofA, CLSA, Nomura, Macquarie, JPMorgan, Goldman Sachs, Citigroup, UBS, Deutsche Bank, Credit Suisse, HSBC, BofA Securities, Axis Capital, Antique Stock Broking, Sharekhan, PhillipCapital, Nirmal Bang, Centrum Broking, Anand Rathi, Ventura, Marwadi, Geojit, Trustline, and IIFL. The consensus rating is overwhelmingly BUY, reflecting the structural turnaround narrative.

6.1 Consensus Snapshot

6.2 Major Brokerage Views (Selected)

6.3 Consensus EPS Estimates (FY27E, FY28E, FY29E)

6.4 Recent Rating Actions (Last 6 Months)

6.5 Street View — Bull vs Bear

§7 — Shareholding Pattern

Lupin's shareholding structure is dominated by the founder Gupta family (promoters), with institutional ownership (FIIs + DIIs) collectively at ~47% — a healthy, diversified institutional base that has actually strengthened over 5 years as DIIs and FIIs both grew their stakes.

7.1 Latest Quarterly Shareholding (Mar 2026)

7.2 10-Year Shareholding Evolution

7.3 Top Institutional Holders (Indicative)

7.4 Promoter Group Detail

7.5 Shareholding Quality Indicators

§8 — Key Risks

No equity research is complete without a rigorous risk assessment. While Lupin's structural story is compelling, investors must monitor six critical risk vectors that could derail the thesis. We size each by probability × impact and provide monitoring KPIs.

8.1 Risk Matrix

8.2 USFDA Compliance — Detailed View

8.3 US Generic Pricing Risk

8.4 India-Specific Risks

8.5 R&D & Pipeline Risks

8.6 Currency & Macro Risks

8.7 Capital Allocation & Governance Risks

8.8 ESG & Sustainability Risks

8.9 Risk-Reward Recap

§9 — Investment Thesis

After dissecting business model, quarterly trajectory, 5-year financials, peer positioning, DCF valuation, analyst consensus, shareholding pattern, and risk vectors, our investment thesis on Lupin rests on five pillars. We BUY with a 12-month target of ₹2,750 (20.7% upside) and a bull-case fair value of ₹3,200 (40% upside).

9.1 Pillar 1 — The US Pricing Cycle Has Bottomed

Lupin's US business spent 2018–2023 in a brutal price-erosion cycle that drove the consolidated OPM from 28% in FY15 to 1% in FY22. But the trajectory has reversed: US price erosion slowed to single digits in 2024, and net price realization improved in 2025–26 as (a) older off-patent molecules stabilized and (b) Lupin shifted mix to complex generics (Mirabegron ER, Solenor, Tolvaptan) and biosimilars (Etanercept, Ranibizumab). The Q4FY26 print of US revenue at ₹2,800 Cr (+25% YoY) validates this thesis. With OPM at 33% in Q4FY26 (vs trough of 13% in Q1FY24), the margin recovery is real, not cyclical, and is supported by a 12–15 complex-generic launches per year through FY28.

9.2 Pillar 2 — India Chronic Franchise Is a Compounding Engine

The India formulations business is the quiet compounder of the Lupin story. It generates ~32% of revenue, ~50% of operating profit, and ~80% of cash at OPM north of 30%. The franchise is anchored in chronic therapies (cardiac, diabetes, respiratory) that account for >60% of India sales and grow at 12–15% annually — outpacing the acute therapy market (~7–8% growth). With India chronic-disease prevalence rising on the back of urbanization, sedentary lifestyles, and aging demographics, and Lupin's promoted brands (Cilacar, Tonact, Biselect, Glugon, Foster) enjoying top-3 ranks in their categories, the franchise should compound at ~14–16% CAGR for FY27–FY30, with margin expansion as the chronic mix deepens.

9.3 Pillar 3 — Margin Recovery Has Further to Run

Lupin's OPM trajectory from 1% (FY22) → 32% (FY26) is one of the most dramatic in pharma history, but we believe further expansion to 33–35% is achievable because: (a) Operating leverage on rising sales (fixed-cost absorption), (b) Manufacturing efficiency via plant-level debottlenecking, (c) Mix shift to complex generics (5–10% of US revenue today, 20%+ by FY28), and (d) Lower remediation costs as the Goa API issue resolves. The 5-year average OPM of ~17% is now an obsolete benchmark — the new steady-state OPM is 30%+, supported by 30.3% ROCE and 29.1% ROE in FY26. EPS upgrades are likely as the Street's FY27E OPM estimates of 30% look conservative vs management's track record.

9.4 Pillar 4 — Capital Returns and Free Cash Flow Inflection

The balance sheet transformation is underappreciated. Lupin's Net Debt/Equity went from 0.27x in FY22 to 0.13x in FY26, while FCF went from -₹531 Cr to +₹5,527 Cr. With ₹3,000–3,500 Cr of net cash projected by FY27 and CFO/OP sustained at 95–100%, Lupin has the optionality to: (a) Increase dividend payout from 15% to 25–30% (potential DPS doubling to ~₹30/share by FY28), (b) Execute a ₹2,000–3,000 Cr buyback at trough valuations, (c) Make a strategic acquisition in complex injectables / specialty dermatology, and/or (d) Fund capex internally without leveraging the balance sheet. Either way, shareholder yield (dividend + buyback) is likely to rise from ~0.5% to 2–3% by FY28.

9.5 Pillar 5 — Valuation Re-Rating is Justified

At 18.1x TTM P/E, LUPIN trades at a discount to the Indian pharma sector average of ~28x and to Sun Pharma at ~38x, despite delivering peer-leading ROCE of 30% and EPS growth of 88% in Q4FY26. Historically, when Lupin has sustained ROCE > 25% for 2+ years, the stock has re-rated to 22–25x P/E. With OPM sustainably above 30%, EPS doubling from ₹116 (TTM) to ₹235 (FY28E) is plausible, and a 22x P/E re-rating would imply ₹5,170/share in 2-3 years. The base case 20x P/E on FY27E EPS of ₹135 yields ₹2,700, in line with our DCF fair value of ₹2,618. Bull-case 25x P/E on FY28E EPS of ₹165 yields ₹4,125. We anchor on a 12-month target of ₹2,750 (20.7% upside) and a bull-case fair value of ₹3,200 (40.5% upside).

9.6 Catalysts (Next 12–18 Months)

9.7 Final Verdict

9.8 Comparables & Re-Rating Path

9.9 What Could Make Us Wrong

9.10 Closing Statement

Lupin is the cleanest, most differentiated turnaround story in Indian large-cap pharma. It combines (a) US pricing-cycle recovery, (b) India chronic-disease compounding, (c) margin expansion to peer-leading 32%+ OPM, (d) FCF inflection from negative ₹531 Cr to ₹5,527 Cr in 5 years, and (e) a 30%+ ROCE profile that the market has only partially recognized. At 18.1x trailing P/E and 13x FY27E EV/EBITDA, the valuation is conservative for a 30%+ ROCE business compounding 14–16%. The risk-reward is favorable: base case 20.7% upside, bull case 40.5%, bear case -16.6%. We BUY with conviction and a 12-month target of ₹2,750. Investors should accumulate on dips to ₹2,200 and hold for 18–24 months. Lupin is our top pharma pick for FY27.

Appendix A — Key Definitions

Appendix B — Source References

Appendix C — Important Disclaimers

Final Word: BUY LUPIN. Target ₹2,750. Time Horizon 18–24 months. Conviction: High. Reward-to-Risk: 1:2.4 to base, 1:4 to bull.

Lupin: Best-in-class pharma turnaround. Quality compounder. Margin leader. Free cash flow generator. 30%+ ROCE. Now at a reasonable valuation.